Compare IQV & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | TCOM |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 40.6B |
| IPO Year | 2013 | 2003 |
| Metric | IQV | TCOM |
|---|---|---|
| Price | $235.75 | $62.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $242.60 | $80.00 |
| AVG Volume (30 Days) | 1.2M | ★ 5.0M |
| Earning Date | 02-05-2026 | 02-23-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | N/A | ★ 86.40 |
| EPS | ★ 7.30 | 6.25 |
| Revenue | ★ $15,904,000,000.00 | $8,393,499,281.00 |
| Revenue This Year | $6.14 | $18.23 |
| Revenue Next Year | $5.44 | $13.78 |
| P/E Ratio | $32.26 | ★ $9.92 |
| Revenue Growth | 3.85 | ★ 17.45 |
| 52 Week Low | $134.65 | $51.35 |
| 52 Week High | $247.05 | $78.99 |
| Indicator | IQV | TCOM |
|---|---|---|
| Relative Strength Index (RSI) | 50.44 | 35.20 |
| Support Level | $227.99 | $61.64 |
| Resistance Level | $244.16 | $64.24 |
| Average True Range (ATR) | 5.81 | 1.73 |
| MACD | -0.83 | -0.60 |
| Stochastic Oscillator | 39.14 | 9.92 |
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.